Evaluation of the efficacy of vaginal product based on chamomile for the treatment of dyspareunia

The effect of vaginal product based on chamomile for treatment of women with dyspareunia

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT201702197511N3

Enrollment

Registered

2017-10-22

Start date

2017-10-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyspareunia. Dyspareunia

Interventions

Intervention 1: Intervention group: Immediately after the end of menstruation, every night before bed for 10 nights, a vaginal tablet of chamomile is placed at the upper end of vagina with applicator.

Treatment - Drugs

Placebo

Intervention group: Immediately after the end of menstruation, every night before bed for 10 nights, a vaginal tablet of chamomile is placed at the upper end of vagina with applicator

Control group: Immediately after the end of menstruation, every night before bed for 10 nights, a vaginal tablet of placebo is placed at the upper end of vagina with applicator

Eligibility

Sex/Gender

Female

Age

18 Years to 49 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients aged 18 to 49 years old married women with dyspareunia at least during the 3 last months; having intercourse at least once during a month; conscious informed consent; normal gynecological examination; using non-hormonal contraceptives. Exclusion criteria: use of hormonal drugs, anti-hypertensive and anti-depressant drugs over a month before beginning of the study; pregnancy; breast-feeding; Menopause.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain during intercourse. Timepoint: before & after the study. Method of measurement: VAS Questionnaire.	—

Secondary

Measure	Time frame
Lubrication of vagina during intercourse. Timepoint: before & after the study. Method of measurement: FSFI questionnaire.;Arousal during intercourse. Timepoint: before & after the study. Method of measurement: FSFI questionnaire.;Desire during intercourse. Timepoint: before & after the study. Method of measurement: FSFI questionnaire.;Orgasm during intercourse. Timepoint: before & after the study. Method of measurement: FSFI questionnaire.;Satisfaction during intercourse. Timepoint: before & after the study. Method of measurement: FSFI questionnaire.	—

Measure

Time frame

Lubrication of vagina during intercourse. Timepoint: before & after the study. Method of measurement: FSFI questionnaire.;Arousal during intercourse. Timepoint: before & after the study. Method of measurement: FSFI questionnaire.;Desire during intercourse. Timepoint: before & after the study. Method of measurement: FSFI questionnaire.;Orgasm during intercourse. Timepoint: before & after the study. Method of measurement: FSFI questionnaire.;Satisfaction during intercourse. Timepoint: before & after the study. Method of measurement: FSFI questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDoctor Marzieh Qaraaty

Golestan University of Medical Sciences

gharaaty1387@yahoo.com, dr.qaraati@goums.ac.ir+98 17 3254 1065

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026